OBJECTIVE: The apolipoprotein A-I (apoA-I) mimetic peptide 4F favors the differentiation of human monocytes to an anti-inflammatory phenotype and attenuates lipopolysaccharide (LPS)-induced inflammatory responses. We investigated the effects of LPS on the Toll-like receptor (TLR) signaling pathway in 4F-differentiated monocyte-derived macrophages. METHODS AND RESULTS: Monocyte-derived macrophages were pretreated with 4F or vehicle for 7 days. 4F downregulated cell-surface TLRs (4, 5, and 6) as determined by flow cytometry. 4F attenuated the LPS-dependent upregulation of genes encoding TLR1, 2, and 6 and genes of the MyD88-dependent (CD14, MyD88, TRAF6, interleukin-1 receptor-associated kinase 4, and inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta) and MyD88-independent (interferon regulatory factor 3, TANK-binding kinase 1, and Toll-interleukin 1 receptor domain-containing adaptor-inducing interferon-β) pathways as determined by microarray analysis and quantitative reverse transcriptase polymerase chain reaction. Functional analyses of monocyte-derived macrophages showed that 4F reduced LPS-dependent TLR4 recycling, phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha, activation and translocation of nuclear factor-κB and inhibited the secretion of tumor necrosis factor-α and interleukin-6 induced by LPS or lipoteichoic acid. These changes were associated with depletion of cellular cholesterol and caveolin, components of membrane lipid rafts. CONCLUSIONS: These data suggest that disruption of rafts by 4F alters the assembly of TLR-ligand complexes in cell membranes and inhibits proinflammatory gene expression in monocyte-derived macrophages, thus attenuating the responsiveness of macrophages to LPS.
OBJECTIVE: The apolipoprotein A-I (apoA-I) mimetic peptide 4F favors the differentiation of human monocytes to an anti-inflammatory phenotype and attenuates lipopolysaccharide (LPS)-induced inflammatory responses. We investigated the effects of LPS on the Toll-like receptor (TLR) signaling pathway in 4F-differentiated monocyte-derived macrophages. METHODS AND RESULTS: Monocyte-derived macrophages were pretreated with 4F or vehicle for 7 days. 4F downregulated cell-surface TLRs (4, 5, and 6) as determined by flow cytometry. 4F attenuated the LPS-dependent upregulation of genes encoding TLR1, 2, and 6 and genes of the MyD88-dependent (CD14, MyD88, TRAF6, interleukin-1 receptor-associated kinase 4, and inhibitor of kappa light polypeptide gene enhancer in B-cells, kinase beta) and MyD88-independent (interferon regulatory factor 3, TANK-binding kinase 1, and Toll-interleukin 1 receptor domain-containing adaptor-inducing interferon-β) pathways as determined by microarray analysis and quantitative reverse transcriptase polymerase chain reaction. Functional analyses of monocyte-derived macrophages showed that 4F reduced LPS-dependent TLR4 recycling, phosphorylation of nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha, activation and translocation of nuclear factor-κB and inhibited the secretion of tumor necrosis factor-α and interleukin-6 induced by LPS or lipoteichoic acid. These changes were associated with depletion of cellular cholesterol and caveolin, components of membrane lipid rafts. CONCLUSIONS: These data suggest that disruption of rafts by 4F alters the assembly of TLR-ligand complexes in cell membranes and inhibits proinflammatory gene expression in monocyte-derived macrophages, thus attenuating the responsiveness of macrophages to LPS.
Authors: G Datta; M Chaddha; S Hama; M Navab; A M Fogelman; D W Garber; V K Mishra; R M Epand; R F Epand; S Lund-Katz; M C Phillips; J P Segrest; G M Anantharamaiah Journal: J Lipid Res Date: 2001-07 Impact factor: 5.922
Authors: Zhenghao Zhang; Geeta Datta; Yun Zhang; Andrew P Miller; Paulina Mochon; Yiu-Fai Chen; John Chatham; G M Anantharamaiah; C Roger White Journal: Am J Physiol Heart Circ Physiol Date: 2009-06-26 Impact factor: 4.733
Authors: Lesley E Smythies; C Roger White; Akhil Maheshwari; M N Palgunachari; G M Anantharamaiah; Manjula Chaddha; Ashish R Kurundkar; Geeta Datta Journal: Am J Physiol Cell Physiol Date: 2010-03-10 Impact factor: 4.249
Authors: Xuewei Zhu; John S Owen; Martha D Wilson; Haitao Li; Gary L Griffiths; Michael J Thomas; Elizabeth M Hiltbold; Michael B Fessler; John S Parks Journal: J Lipid Res Date: 2010-07-21 Impact factor: 5.922
Authors: Eicke Latz; Alberto Visintin; Egil Lien; Kate A Fitzgerald; Brian G Monks; Evelyn A Kurt-Jones; Douglas T Golenbock; Terje Espevik Journal: J Biol Chem Date: 2002-09-24 Impact factor: 5.157
Authors: Soo-Ho Choi; Aaron M Wallace; Dina A Schneider; Elianne Burg; Jungsu Kim; Elena Alekseeva; Niki Dj Ubags; Carlyne D Cool; Longhou Fang; Benjamin T Suratt; Yury I Miller Journal: JCI Insight Date: 2018-08-23
Authors: Geeta Datta; Philip A Kramer; Michelle S Johnson; Hirotaka Sawada; Lesley E Smythies; David K Crossman; Balu Chacko; Scott W Ballinger; David G Westbrook; Palgunachari Mayakonda; G M Anantharamaiah; Victor M Darley-Usmar; C Roger White Journal: Biochem J Date: 2015-05-01 Impact factor: 3.857
Authors: Humaira Rasheed; Amanda J Phipps-Green; Ruth Topless; Malcolm D Smith; Catherine Hill; Susan Lester; Maureen Rischmueller; Matthijs Janssen; Timothy L Jansen; Leo A Joosten; Timothy R Radstake; Philip L Riches; Anne-Kathrin Tausche; Frederic Lioté; Alexander So; Andre van Rij; Gregory T Jones; Sally P McCormick; Andrew A Harrison; Lisa K Stamp; Nicola Dalbeth; Tony R Merriman Journal: Rheumatology (Oxford) Date: 2016-04-18 Impact factor: 7.580
Authors: Oleg F Sharifov; Xin Xu; Amit Gaggar; Edlue M Tabengwa; C Roger White; Mayakonda N Palgunachari; G M Anantharamaiah; Himanshu Gupta Journal: Inflammation Date: 2014-10 Impact factor: 4.092
Authors: Oleg F Sharifov; Xin Xu; Amit Gaggar; William E Grizzle; Vinod K Mishra; Jaideep Honavar; Silvio H Litovsky; Mayakonda N Palgunachari; C Roger White; G M Anantharamaiah; Himanshu Gupta Journal: PLoS One Date: 2013-05-14 Impact factor: 3.240